Fig.2 PB Dose Fractionation:
Urinary KIM1 in treatment groups

1570. Association Between Vancomycin Area Under the Curve (AUC) and Nephrotoxicity

Anna Poston-Blahnik, PharmD[1]; Ryan P. Moenster, PharmD, FIDSA, BCPS-AQ ID[2];
[1]St. Louis VA Health Care, Saint Louis, Missouri; [2]St. Louis College of Pharmacy/VA
St. Louis Health Care System, St. Louis, Missouri

Session: 162. PK/PD and Susceptibility Testing
Friday, October 4, 2019: 12:15 PM

Background. It is unclear whether increased vancomycin area under the curve (AUC) contributes to acute kidney injury (AKI) risk.

Methods. This retrospective cohort study was undertaken to determine whether vancomycin AUC > 550 is associated with a higher rate of AKI than an AUC < 550. Patients treated with vancomycin for at least 4 days at the St. Louis VA from 1/1/2016–9/31/2018 were included. The primary outcome was AKI (defined as an increase in serum creatinine by 0.3 mg/dL or 50% from baseline). Secondary outcomes included length of stay, readmission, or mortality in 30 days, AKI rate with concurrent antibiotics, and AKI rate with comorbidities. The AUC was calculated as daily dose (in mg) divided by vancomycin clearance. The variables of age ≥ 70, vancomycin AUC ≥ 550, creatinine clearance (CrCl) < 50 mL/minute, concomitant antibiotic administration, vancomycin treatment ≤ 7 days, and the presence of comorbidities were included in a bivariate analysis. Variables with a *P*-value of <0.2 were included in a multivariate logistic regression model.

Results. Two hundred patients were included in the analysis; 100 patients with an AUC ≥ 550, and 100 with an AUC < 500. Only mean vancomycin dose (1722.50 mg vs. 2361.25 mg; *P* < 0.05), mean AUC (465.88 vs. 696.45; *P* < 0.05), and peak SCr (1.22 mg/dL vs. 1.48 mg/dL; *P* = 0.015) were significantly different between groups; AUC < 550 vs. AUC ≥ 550, respectively. Acute kidney injury occurred in 22% (44/200) of all patients; 42% (42/100) with a calculated AUC ≥ 550 developed AKI compared with 2% (2/100) of patients with an AUC < 550 (*P* < 0.05). The secondary outcomes of concomitant nephrotoxic agents, length of stay, readmission at 30 days, and 30-day mortality were not significantly different between groups. Only age ≥ 70, vancomycin AUC ≥ 550, CrCl < 50 mL/minute, concomitant piperacillin–tazobactam administration, and the presence of comorbidities were included in the multivariate regression. Age ≥ 70, CrCl < 50 mL/minute, and AUC ≥ 550 [OR 49.5 (95% CI 10.1 – 242.3; *P* < 0.05)] were found to be independently associated with risk for developing AKI.

Conclusion. Patients with a calculated vancomycin AUC ≥ 550 were found to have a significantly higher rate of AKI compared with those with an AUC < 550.

1571. Evaluation of a Single Post First Dose Vancomycin Level to Achieve a Goal Vancomycin AUC

Evan Hurley, PharmD[1]; Steven C. Ebert, PharmD, FCCP, FIDSA,[2]; [1]Unitypoint Health, Meriter Hospital, Madison, Wisconsin; [2]University of Wisconsin-Madison, Madison, Wisconsin

Session: 162. PK/PD and Susceptibility Testing
Friday, October 4, 2019: 12:15 PM

Background. The 24-hour area under the serum concentration–time curve (AUC24) is the most defensible measure to predict the effectiveness and toxicity of vancomycin. The optimal method and time point to assess and optimize AUC24, however, have yet to be determined. Measuring a trough concentration at steady state has been the traditional method of monitoring vancomycin, but trough is unreliable at estimating AUC24. More accurate methods for estimating AUC24 are paired sample analysis, or a single optimally timed sample combined with population pharmacokinetics. We wished to optimize AUC24 prior to steady state for earlier goal attainment, thereby decreasing risk of treatment failure, resistance, and/or nephrotoxicity. A single optimally timed single post first dose level may be used to estimate drug clearance and thereby AUC. Based on the post first dose concentration and a

population pharmacokinetic model, clearance is calculated, and the dosing regimen can be adjusted to achieve a desired AUC24. Our institution has enabled pharmacists to obtain post first dose vancomycin levels and make early dose adjustments. The aim of this project is to monitor the accuracy of this method and the outcomes of patients who have received post first dose vancomycin levels and subsequent dose assessment/adjustment.

Methods. Single-center cohort study via electronic chart review of patients with vancomycin therapeutic dose monitoring based on post first dose vancomycin levels obtained between January 2019 and April 2019.

Results. 41 patients were dosed and monitored based on post first dose vancomycin levels. Fourteen patients (34%) required dose adjustments based on the post first dose level. Accuracy of assessment was determined in 15 patients (37%) via a steady-state level used to measure vancomycin clearance and AUC24. At steady-state following dose assessment 14/15 (93%) patients had desired targeted goal AUC24. Only two patients (5%) had greater than a 50% increase in baseline serum creatinine.

Conclusion. Post first dose-level analysis resulted in dose regimen modifications in one-third of patients. This consistently allowed the attainment of goal AUC24 at steady-state.

1572. Evaluation of Vancomycin Levels Following Weight-Based Pre-operative and Re-warming Vancomycin Dosing in Cardiac Surgery

Michael Ruggero, PharmD[1]; Gretchen Redline, PharmD[2];
Stuart Weiss, MD, PhD[1]; Shawn Binkley, BS, PharmD[1]; Keith W. Hamilton, MD[1];
[1]Hospital of the University of Pennsylvania, Haddonfield, New Jersey; [2]Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Session: 162. PK/PD and Susceptibility Testing
Friday, October 4, 2019: 12:15 PM

Background. Weight-based dosing of vancomycin in the pre-operative setting is standard practice at our institution based on the 2013 Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Our antimicrobial subcommittee recommended a weight-based dosing (15 mg/kg/dose) approach to negate the need for a subsequent vancomycin dose during rewarming in cases requiring cardiopulmonary bypass (CPB). However, after discussion with all perioperative stakeholders, administration of vancomycin 1 g intravenously for all patients on CPB at rewarming continued. The aim of this study was to determine whether subsequent rewarming vancomycin doses contributed to the development of postoperative acute kidney injury (AKI).

Methods. This was a prospective cohort study of all cardiac surgery patients undergoing surgery from April 16, 2018 through April 27, 2018 for the development of AKI as defined by RIFLE criteria. Institutional guidelines recommend vancomycin as perioperative prophylaxis in all cardiac surgery cases with a preoperative 15 mg/kg dose, a 1 g rewarming dose, and nomogram-based post-operative dosing. Vancomycin troughs were obtained prior to the first post-operative dose in the intensive care unit. Serum creatinine was recorded on the post-op day (POD) 0, POD 1, and POD 2.

Results. Data were collected on 54 patients over a 2-week period. The median age was 64 years of age, with 41 (76%) male patients. Seven patients (13%) had a prior diagnosis of chronic kidney disease (CKD). Post-op AKI developed in 8 patients (15%) by POD 7; two of which had CKD at baseline. All patients received appropriate preoperative and postoperative dosing. Forty-nine (91%) patients had trough levels obtained, with the median trough 7.6 µg/mL (range 2 – 15.9 µg/mL) prior to the first nomogram-based post-operative vancomycin dose. Higher rates of AKI were associated with a longer duration of CPB rather than vancomycin levels obtained.

Conclusion. The current practice of redosing 1 g vancomycin at rewarming did not appear to contribute higher rates of AKI. In addition, all vancomycin trough levels reviewed were less than 20 µg/mL. Levels observed in this study are lower than previously described in the literature to cause nephrotoxicity. Further evaluation of vancomycin use in this setting is warranted

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients

Jiajun Liu, PharmD[1]; Michael Neely, MD[2];
Jeffrey Lipman, MBBCh (Wits), DA (SA), FFA (SA), FFA (Crit Care)(SA), FCICM, MD (Research)[3]; Fekade B. Sime, PhD, S.Aust.[4];
Jason Roberts, Bachelor of Pharmacy with Honours Class 1, PhD[5];
Patrick J. Kiel, PharmD[6]; Marc H. Scheetz, PharmD, MSc[1]; [1]Midwestern University/Northwestern Memorial Hospital, Downers Grove, Illinois; [2]Children Hospital Los Angeles, Los Angeles, California; [3]UQ Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Queensland, ; [4]Centre for Translational Anti-infective Pharmacodynamics, UQ Centre for Clinical Research, Brisbane, Queensland, Australia; [5]Centre for Translational Anti-infective Pharmacodynamics, UQ Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; [6]Indiana University School of Medicine, Indianapolis, Indiana

Session: 162. PK/PD and Susceptibility Testing
Friday, October 4, 2019: 12:15 PM

Background. Cefepime (CEF) is commonly used for adult and pediatric infections. Several studies have examined CEF's pharmacokinetics (PK) in various populations; however, a unifying PK model for adult and pediatric subjects does not yet exist. We developed a combined population model for adult and pediatric patients and validated the model.